Table 1. Patient Characteristics of Included Studies.
| First Author | No. of Patients | Age (Years) | PSA (ng/mL) Median (Range) | Gleason Score Median (Range) | Pathological T Stage† (No. of Patients) |
|---|---|---|---|---|---|
| Baco (13) | 111 | 64 (45–75) | 8.9 (2.5–44) | 7 (6–9) | T2a (8), T2b (2), T2c (61), T3a (37), T3b (3) |
| Caglic (25) | 75 | 65 (57–67) | 8.5 (5.7–10.4) | 7 (6–10) | T2 (27), T3a (41), T3b (7) |
| Costa (26) | 80 | 64* (46–78) | 8.0* (1.8–46.3) | 7 (6, 7, ≥ 8) | T2 (40), T3 (40) |
| Granja (27) | 92 | 61* (39–78) | 9.3* (NA) | NA | T2 (73), T3 (19) |
| Kongnyuy (28) | 379 | 60 (38–76) | 5.5 (0.1–55.7) | 7 (6, 7, ≥ 8) | NA |
| Krishna (29) | 149 | 63* (NA) | 7.8* (0.0–73.0) | NA | NA |
| Matsuoka (30) | 210 | 67 (50–81) | 7.0 (2.9–30.0) | 7 (5–10) | NA |
| Mehralivand (31) | 553 | 60* (38–76) | 6.3 (0.2–170.0) | NA | NA |
| Onay (14) | 105 | 62* (40–77) | 8.0* (2.1–46.0) | 7 (6–9) | T2a (7), T2b (2), T2c (72), T3a (19), T3b (5) |
| Outwater (32) | 30 | NA (NA) | 11.3* (3.7–30.0) | NA | NA |
| Rosenkrantz (15) | 90 | 64* (NA) | 9.0* (NA) | NA | NA |
| Woo (16) | 185 | 67* (45–79) | 10.2* (0.5–123.0) | 7 (6–9) | T2a (32), T2b (3), T2c (94), T3a (41), T3b (15) |
| Yu (33) | 77 | 63* (45–90) | 10.7* (NA) | NA | T2a (6), T2b (9), T2c (28), T3a (22), T3b (5), T3c (7) |
*Mean, †Reported pathological T stage in addition to histopathological extraprostatic extension status. NA = not available, PSA = prostate-specific antigen